Brachytherapy News and Research

RSS
Brachytherapy is a minimally invasive procedure that involves the use of radioactive seeds the size of rice grains. Brachytherapy, an out-patient procedure, usually takes 45 minutes to an hour to perform. Most patients can return to their normal activities within days. The success rates of prostate brachytherapy have compared favorably with success rates of radical prostatectomy and external beam radiation. In comparison studies, prostate brachytherapy has shown to have a favorable side effect profile when compared with other modalities. Clinical studies have shown that prostate brachytherapy has a cure rate of 94% for appropriately selected patients.
Researchers develop gLQ Model to determine optimal dose level, treatment schedules for high-dose radiation therapies

Researchers develop gLQ Model to determine optimal dose level, treatment schedules for high-dose radiation therapies

Leon-Berard Cancer Center to install CyberKnife VSI System

Leon-Berard Cancer Center to install CyberKnife VSI System

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

First time use of ExAblate MR Guided Focused Ultrasound System for prostate cancer treatment

First time use of ExAblate MR Guided Focused Ultrasound System for prostate cancer treatment

Researcher develops new plaque brachytherapy technique to treat eye cancer

Researcher develops new plaque brachytherapy technique to treat eye cancer

Varian Medical Systems enters $225M accelerated share repurchase agreement with Bank of America

Varian Medical Systems enters $225M accelerated share repurchase agreement with Bank of America

Varian to showcase new Gated RapidArc technology at 2010 CHINA-HOSPEQ exhibition

Varian to showcase new Gated RapidArc technology at 2010 CHINA-HOSPEQ exhibition

Theragenics reports consolidated revenue of $20.8M for second-quarter 2010

Theragenics reports consolidated revenue of $20.8M for second-quarter 2010

Varian Medical Systems board authorizes additional 8 million common stock repurchase program

Varian Medical Systems board authorizes additional 8 million common stock repurchase program

Surgery offers high survival rate for prostate cancer patients: Study

Surgery offers high survival rate for prostate cancer patients: Study

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

Hybrid Linac-MR imaging system tracks cancer tumors in real time

Hybrid Linac-MR imaging system tracks cancer tumors in real time

John Theurer Cancer Center to acquire TrueBeam system for treating cancer patients

John Theurer Cancer Center to acquire TrueBeam system for treating cancer patients

Three different methods for accurately measuring breast density

Three different methods for accurately measuring breast density

An overview of AAPM annual meeting

An overview of AAPM annual meeting

Philadelphia to host 52nd annual meeting of American Association of Physicists in Medicine

Philadelphia to host 52nd annual meeting of American Association of Physicists in Medicine

Premier, Xoft execute group purchasing contract

Premier, Xoft execute group purchasing contract

Varian adopts Varicent for administering Sales Performance Management needs

Varian adopts Varicent for administering Sales Performance Management needs

Oncura signs distribution agreement with Theragenics for palladium-103 brachytherapy seeds

Oncura signs distribution agreement with Theragenics for palladium-103 brachytherapy seeds

Highlights of AAPM 52nd meeting

Highlights of AAPM 52nd meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.